Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

eral cases of QTc prolongation were reported early in the study, but most resolved following a dose adjustment, and no Grade 4 cases have been reported in the subset of 62 patients.  One case of Grade 4 QTc prolongation has been observed in the entire study of 333 patients.  Management of other adverse events is also being explored with dose modifications in the ongoing study.

Detection of Phosphorylated and Total FLT3 and STAT5 in Whole Blood;

Modulation by Quizartinib (AC220) from Phase I and II Trials in AML

The pharmacodynamic effects of quizartinib treatment in AML patients was assessed using whole blood samples from patients enrolled in a previously performed Phase 1 study, and from the 62 patient subset in the Phase 2 study described above.  Proprietary and customized immunoassays were developed, optimized and validated at Ambit to detect both total (t) and phosphorylated (p) levels of FLT3, as well as the downstream signaling protein STAT5.  Blood samples were examined prior to treatment with quizartinib on Day 1 of treatment and again after either 8 or 15 days of treatment, depending upon study. 

Results from this assay demonstrated that following administration of quizartinib there was a profound, immediate and sustained pharmacodynamic effect in inhibiting both FLT3 and the subsequent downstream phosphorylation of the biologically important signaling protein, STAT5.  A mean pFLT3 inhibition of 80 percent was observed within 24-hours of the first dose, and there was a strong correlation with inhibiting phosphorylation of STAT5 (p < 0.007).  These findings support the linkage between FLT3 activation and downstream STAT5 activation, and demonstrate the ability of quizartinib to inhibit both of these important signaling molecules that are involved in the pathology of FLT3-ITD positive AML.  Results at later time points showed that approximately one half (47 per
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... May 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: YONG ), ("Yongye" ... and animal nutrient products in the,People,s Republic of China ("PRC"), ... in May 2010 . , ... The date, time and location of Yongye,s ...
... , NEW YORK , May 10 ... "AOBO"), a pharmaceutical,company dedicated to improving health through the development, manufacture and,commercialization of ... results for the first quarter ended March,31, 2010 . , ... First Quarter 2010 Financial Performance ...
... , May 7 iCyt, a wholly owned ... of their new flow cytometry products at CYTO2010, the Congress ... in Seattle . ( http://www.isac-net.org/ ) These new products ... since iCyt was acquired by Sony in February of this ...
Cached Biology Technology:Yongye International to Present at Upcoming Investor Conferences 2Yongye International to Present at Upcoming Investor Conferences 3American Oriental Bioengineering Reports First Quarter 2010 Financial Results 2American Oriental Bioengineering Reports First Quarter 2010 Financial Results 3American Oriental Bioengineering Reports First Quarter 2010 Financial Results 4American Oriental Bioengineering Reports First Quarter 2010 Financial Results 5American Oriental Bioengineering Reports First Quarter 2010 Financial Results 6American Oriental Bioengineering Reports First Quarter 2010 Financial Results 7American Oriental Bioengineering Reports First Quarter 2010 Financial Results 8iCyt Unveils New Flow Cytometry Products in Collaboration with Sony at CYTO2010 2iCyt Unveils New Flow Cytometry Products in Collaboration with Sony at CYTO2010 3
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... An organelle called the nucleolus resides deep within the ... critical functions: it manufactures ribosomes, the molecular machines that ... proteins that do the work of life. , ... Sciences Division of the Department of Energy's Lawrence Berkeley ...
... A solar-powered robot with 20/20 vision, on a search-and-destroy quest ... crop rows at the experimental fields at the University of ... weeds while significantly reducing herbicide use. , The robot uses ... on a frame on top of the machine to give ...
... Women infected with dormant toxoplasmosis are more likely to ... negative, according to research by S. Kankova and colleagues ... University; the Centre of Reproductive Medicine; and GynCentrum, in ... of the parasite Toxoplasma gondii in the mothers' blood, ...
Cached Biology News:Regulating the nuclear architecture of the cell 2Regulating the nuclear architecture of the cell 3Regulating the nuclear architecture of the cell 4Regulating the nuclear architecture of the cell 5New system could drastically reduce herbicide use 2New system could drastically reduce herbicide use 3Bad blood between boys and girls 2
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: